Articles From: inContact CEO Paul Jarman and CFO Greg Ayers to Present at the Oppenheimer 16th Annual Technology, Internet & Communications Conference to Incyte Reports 2013 Fourth-Quarter and Year-End Financial Results; Provides 2014 Financial Guidance; Updates Shareholders on Key Clinical Programs


SALT LAKE CITY , Jan.
Sign-up for inContact CEO Paul Jarman to Present at the 16th Annual Needham Growth Conference investment picks
2014/3/10
SALT LAKE CITY , March 10 , 2014 /PRNewswire/ -- inContact (NASDAQ: SAAS) , the leading provider of cloud contact center software and contact center agent optimization tools, today announced that inContact CEO Paul Jarman  will present at the following investor conferences: Piper Jaffray Technology, Media and Telecommunications Conference – Tuesday, March 11, 2014 Where: Le Parker Meridien in New York, NY Presentation: 1:00 PM EST .
Sign-up for inContact CEO Paul Jarman to Present at Upcoming Investor Conferences investment picks
2014/1/29
SALT LAKE CITY , Jan.
Sign-up for inContact Personal Connection™ Outbound Solution Wins TMC's CUSTOMER Magazine 2014 Product of the Year Award investment picks
2013/10/1
Ovum's Vendor Decision Matrix Names inContact to its Shortlist as a Best-of-Breed Solution SALT LAKE CITY , Oct.
Sign-up for inContact Recognized as Market Leader in Ovum's Multichannel Cloud Contact Center Report investment picks
2014/2/13
- Fourth Quarter Software Segment Revenues of $19.4 million and $68.9 million for full year 2013, up 26% for the year - 85 contracts signed representing 40% year over year bookings growth - Expanding distribution channel with 45 active partners contributing 53% of Q4 bookings SALT LAKE CITY , Feb.
Sign-up for inContact Reports Fourth Quarter and Full Year 2013 Financial Results investment picks
Company Achieves Record Bookings, Year-Over-Year Software Revenue Growth of 26% and Consolidated Revenue Growth of 19% SALT LAKE CITY , Aug.
Sign-up for inContact Reports Second Quarter 2013 Financial Results investment picks
- Software Segment Revenues of $17.1 million, up 23% year over year - Bookings at record levels, up 35% over 3rd quarter of prior year - 71 contracts signed, 4 new Fortune 500 customers join the expanding base SALT LAKE CITY , Nov.
Sign-up for inContact Reports Third Quarter 2013 Financial Results investment picks
2014/1/13
SALT LAKE CITY , Jan.
Sign-up for inContact Sets Fourth Quarter and Year-End 2013 Conference Call investment picks
2013/10/15
SALT LAKE CITY , Oct.
Sign-up for inContact Sets Third Quarter 2013 Conference Call investment picks
2013/9/4
Customers and Partners Gather to Share Insights for Building Tomorrow's Contact Center - Today SALT LAKE CITY , Sept.
Sign-up for inContact's Biggest Event of the Year Draws Cloud Contact Center Industry Thought Leaders investment picks
2014/4/15
RealPage, Inc. (NASDAQ: RP ) introduces email service enhancement Instant Call Reply to its contact center leasing suite.
Sign-up for Increase Property Visits With New Service From RealPage Contact Center investment picks
2014/1/31
Ledyard Financial Group (Ticker Symbol: LFGP) announced today a $0.04 increase to its quarterly dividend.
Sign-up for Increase to Quarterly Dividend Declared by Ledyard Financial Group investment picks
Company Increases Presence in Europe, Asia, Middle East, Africa and Latin America BROOMFIELD, Colo.
Sign-up for Increased Demand for High-Quality Content Delivery Spurs Level 3 To Expand Global CDN Footprint investment picks
JERUSALEM--Increased natural gas production was not enough to increase profits for Israeli holding company Delek Group Ltd.
Sign-up for Increased Natural Gas Production Fails to Boost Delek Group's Profit investment picks
Rising rig counts throughout the United States last week are a promising sign for shareholders of rising energy company First Titan Corp.
Sign-up for Increased Rig Count Foretells Big Potential Gains for FTTN investment picks
2014/1/27
New Cloud-based Service Enables Real-Time, High-Bandwidth Remote Transfer of Massive Files for Network Broadcast and Media Companies Worldwide BROOMFIELD, Colo.
Sign-up for Increasing Demand to Improve Transfer of Large Media Files Drives Development of Level 3 Cloud Content Exchange investment picks
2014/1/22
If the Affordable Care Act (ACA) is to deliver on its promises, especially in properly coordinating care for the fast-growing population of chronically ill Americans, then delivering health care right to our own homes is increasingly essential.
Sign-up for Increasing Health Care at Home Integral to Success of the Affordable Care Act investment picks
Leading Firms including OppenheimerFunds Look to Broadridge's Access Data for Fund Asset and Sales Data to Grow Assets Under Management LAKE SUCCESS, N.Y. , Oct.
Sign-up for Increasing Need for Market Intelligence and Data Transparency Among Asset Management Firms Drives Momentum at Broadridge's Access Data investment picks
2014/2/19
Incumaker, Inc. (OTC Pink: QMKR) announced today that it has acquired a second Atlanta area CryoMist location and has appointed a Chief Operating Officer.
Sign-up for Incumaker Announces Acquiring Second Atlanta Area CryoMist Location and Appoints COO investment picks
2013/11/19
Incumaker, Inc. (OTC Pinks:QMKR) announced today that it has entered into a Letter of Understanding to acquire one hundred percent of the shares of Wellness Clinics of America, LLC.
Sign-up for Incumaker Announces Letter of Intent to Acquire Wellness Centers of America investment picks
Incumaker, Inc. (OTC Pinks:QMKR) announced today that it had completed the acquisition of CryoMist I, LLC and CryoMist II, LLC (collectively, “CryoMist”) with a third acquisition of CryoMist III, LLC planned to close by early 2014.
Sign-up for Incumaker Completes Acquisition of Cryogenic Therapy Company investment picks
2014/2/5
Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck’s investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.
Sign-up for Incyte Announces Clinical Trial Collaboration with Merck to Evaluate Combination of Two Novel Immunotherapies investment picks
2014/3/7
Incyte Corporation (Nasdaq: INCY) today announced that a pivotal Phase III trial of ruxolitinib compared to best available therapy in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea has met its primary endpoint of achieving phlebotomy independence and reducing spleen size by 35 percent or more.
Sign-up for Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera investment picks
Incyte Corporation (Nasdaq: INCY) today announced its intention to offer, subject to market and other conditions, $350 million aggregate principal amount of convertible senior notes due 2018 and $350 million aggregate principal amount of convertible senior notes due 2020 in a private placement to qualified institutional buyers pursuant to an exemption from the registration requirements of the Securities Act of 1933.
Sign-up for Incyte Announces Proposed Offering of $700 Million of Convertible Senior Notes investment picks
2013/11/14
Incyte Corporation (Nasdaq: INCY) today announced that it has completed its previously announced private placement of $750 million aggregate principal amount of its convertible senior notes, including notes issued upon the exercise in full of the initial purchasers’ option to purchase additional notes.
Sign-up for Incyte Completes Offering of $750 Million of Convertible Senior Notes investment picks
2014/1/13
Incyte Corporation (Nasdaq:INCY) announced today that Hervé Hoppenot, former President of Novartis Oncology, has been named President and Chief Executive Officer of Incyte, effective immediately.
Sign-up for Incyte Names Hervé Hoppenot President and Chief Executive Officer investment picks
2013/8/21
Incyte Corporation (Nasdaq: INCY) announced top-line results of the Phase II, randomized, double-blind, placebo-controlled RECAP trial of ruxolitinib, its oral JAK1 and JAK2 inhibitor, in combination with capecitabine in patients with recurrent or treatment refractory metastatic pancreatic cancer.
Sign-up for Incyte Provides Top-Line Results from Phase II Proof-of-Concept Trial of Ruxolitinib in Patients with Refractory Metastatic Pancreatic Cancer investment picks
2014/2/12
Incyte Corporation (Nasdaq: INCY) today reported 2013 fourth-quarter and year-end financial results, including revenue from Jakafi ® (ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF). The Company also provided 2014 financial guidance and highlighted multiple achievements in its clinical programs, including agreement with the FDA for a Special Protocol Assessment (SPA) for a registration trial of ruxolitinib in patients with advanced or metastatic pancreatic cancer.
Sign-up for Incyte Reports 2013 Fourth-Quarter and Year-End Financial Results; Provides 2014 Financial Guidance; Updates Shareholders on Key Clinical Programs investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: inContact CEO Paul Jarman and CFO Greg Ayers to Present at the Oppenheimer 16th Annual Technology, Internet & Communications Conference to Incyte Reports 2013 Fourth-Quarter and Year-End Financial Results; Provides 2014 Financial Guidance; Updates Shareholders on Key Clinical Programs
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity